AKBA vs. VSTM, XOMA, FBLG, INZY, EPIX, NBTX, ELYM, RAPT, XBIT, and XERS
Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Verastem (VSTM), XOMA (XOMA), FibroBiologics (FBLG), Inozyme Pharma (INZY), ESSA Pharma (EPIX), Nanobiotix (NBTX), Eliem Therapeutics (ELYM), RAPT Therapeutics (RAPT), XBiotech (XBIT), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical preparations" industry.
Verastem (NASDAQ:VSTM) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends.
Akebia Therapeutics has higher revenue and earnings than Verastem. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.
Verastem has a net margin of 0.00% compared to Verastem's net margin of -22.99%. Verastem's return on equity of 0.00% beat Akebia Therapeutics' return on equity.
In the previous week, Akebia Therapeutics had 1 more articles in the media than Verastem. MarketBeat recorded 14 mentions for Akebia Therapeutics and 13 mentions for Verastem. Akebia Therapeutics' average media sentiment score of 0.38 beat Verastem's score of 0.36 indicating that Verastem is being referred to more favorably in the media.
Verastem received 185 more outperform votes than Akebia Therapeutics when rated by MarketBeat users. Likewise, 65.17% of users gave Verastem an outperform vote while only 63.96% of users gave Akebia Therapeutics an outperform vote.
88.4% of Verastem shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 2.2% of Verastem shares are held by insiders. Comparatively, 3.8% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Verastem has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.
Verastem presently has a consensus target price of $28.79, indicating a potential upside of 139.48%. Akebia Therapeutics has a consensus target price of $5.00, indicating a potential upside of 287.60%. Given Verastem's higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Verastem.
Summary
Akebia Therapeutics beats Verastem on 9 of the 17 factors compared between the two stocks.
Get Akebia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akebia Therapeutics Competitors List
Related Companies and Tools
